Pharmacologic Management of Acute Heart Failure: A Review

Abstract

Because of improved social and medical standards in the western world, the average age of the population continues to increase. This altering demographic profile has its impact on the surgical population, resulting in a dramatic increase in the number of patients with exten sive cardiovascular disease, presenting for either car diac or noncardiac surgery. As a result, the incidence of perioperative acute congestive heart failure (CHF) is a major clinical problem at the present time. For the pharmacologic management of acute CHF, the β-adreno ceptor agonists continue to be the mainstay of therapy, due to their short duration of action and hemodynamic controlability by continuous intravenous infusion. Mono therapy with the phosphodiesterase type III (PDE) inhibi tors appears to be the treatment of choice in selected patients with high systemic vascular resistance or re sidual β-adrenoceptor blockade. Combination therapy especially deserves attention, because this approach allows the enhancement of contractile force, possibly without the side effects associated with the administra tion of high concentrations of one agent alone. New developments including ultrashort-acting PDE inhibi tors, calcium-dependent calcium sensitizers, and cal cium promotors are anxiously awaited.